@article{oai:u-ryukyu.repo.nii.ac.jp:02011316,
 author = {Tome, Yasunori and Kimura, Hiroaki and Sugimoto, Naotoshi and Tsuchiya, Hiroyuki and Kanaya, Fuminori and Bouvet, Michael and Hoffman, Robert M.},
 issue = {52},
 journal = {Oncotarget},
 month = {Nov},
 note = {Echistatin, a cyclic RGD peptide, which is an antagonist of α_vβ_3 integrin (disintegrin), inhibited human osteosarcoma in the chick chorioallontoic membrane (CAM) model and tumor growth and pulmonary metastases in a nude mouse orthotopic model. A high-metastatic variant of human osteosarcoma, 143B-LM4, overexpressing α_vβ_3 integrin was used. Tumor angiogenesis by high-metastatic variant 143B-LM4 cells in the CAM was significantly inhibited by echistatin (P<0.05) as was overall growth. A doxorubicin (DOX)-echistatin combination inhibited orthotopic tumor growth compared to untreated control (P<0.01) or DOX alone (P<0.05) in nude mice. Tumor-bearing mice treated with the DOX-echistatin combination survived longer than those treated with DOX alone or control PBS (P<0.01 and P<0.01, respectively). Echistatin also inhibited experimental lung metastasis of 143B-LM4 cells in nude mice. These results suggest that DOX in combination with a disintegrin has potential to treat osteosarcoma and that α_vβ_3 integrin may be a target for osteosarcoma., 論文},
 pages = {87031--87036},
 title = {The disintegrin echistatin in combination with doxorubicin targets high-metastatic human osteosarcoma overexpressing α_νβ_3 integrin in chick embryo and nude mouse models},
 volume = {7},
 year = {2016}
}